Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
393
datasets available to search
ShareScore release 0.9.0
Dataset results
393 results for “mRNA vaccine”
Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine
ClinicalTrials.gov study NCT04900467. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines
ClinicalTrials.gov study NCT05668065. IPD Sharing: NO. Countries: 1. Publications: 7.
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
ClinicalTrials.gov study NCT05057182. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ClinicalTrials.gov study NCT06067230. IPD Sharing: Not stated. Countries: 4. Publications: 1.
New Generation mRNA Booster Vaccine Against Emerging VOCs
ClinicalTrials.gov study NCT05580159. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ClinicalTrials.gov study NCT05164094. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Modified mRNA Vaccines in Healthy Adults
ClinicalTrials.gov study NCT05397223. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
ClinicalTrials.gov study NCT05373485. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
ClinicalTrials.gov study NCT03382405. IPD Sharing: NO. Countries: 1. Publications: 3.
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
ClinicalTrials.gov study NCT05373472. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
ClinicalTrials.gov study NCT05366322. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
ClinicalTrials.gov study NCT05132855. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ClinicalTrials.gov study NCT05127434. IPD Sharing: NO. Countries: 23. Publications: 2.
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over
ClinicalTrials.gov study NCT05745545. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ClinicalTrials.gov study NCT05085366. IPD Sharing: Not stated. Countries: 13. Publications: 3.
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
ClinicalTrials.gov study NCT05052307. IPD Sharing: NO. Countries: 1. Publications: 2.
Adverse drug reactions to the three doses of the SARS-COV-2 mRNA-1273 vaccine in a cohort of cancer patients of a tertiary hospital
<p><strong>Introduction:</strong> SARS-CoV-2 vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or underrepresented. Information is scarce regarding safety in this population. </p> <p><strong>Methods:</strong> The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This cross sectional study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect tha available information in 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study.</p> <p><strong>Results:</strong> 93 patients met inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs were reported less frequently after the first and second dose than after the third (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with higher ECOG score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that females had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016).</p> <p><strong>Conclusion:</strong> mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.<span></span></p>
Tolerability of COVID-19 mRNA vaccines in patients with postural tachycardia syndrome
<div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded js-article-abstract">Postural tachycardia syndrome (POTS) is a form of autonomic dysregulation. There is increasing evidence that the etiology may be immune-mediated in a subgroup of patients. Patients with POTS often experience an exacerbation of their symptoms associated with infections and often fear the same symptom aggravation after vaccination. With this data we conducted a study to describe the tolerability of mRNA vaccines against COVID-19 and the consequences of a COVID-19 infection on POTS symptoms in our cohort of patients with neuropathic POTS.<br><br>We conducted a standardized, checklist-based interview with 23 patients and recorded the acute side effects of mRNA vaccination, acute symptoms of COVID-19 infection as well as the effects of vaccination and COVID-19 infection on POTS symptoms. The following side effects were assessed in their presence (yes/no) and duration (days): fever, shivering, fatigue, headache, joint pain, muscle pain, nausea, emesis, diarrhea, and reaction at injection site (pain, swelling and cutaneous reaction). For COVID-19 infection, the following additional symptoms were queried: coughing, sore throat, rhinorrhea, breathlessness, loss of taste, loss of smell and chest pain. For each symptom, the presence (yes/no), severity (mild, moderate, severe) and duration (in days) were evaluated. Furthermore, the duration of the infection, need for hospitalization and incapacity for work were assessed. To assess possible exacerbation of POTS symptoms, the presence (yes/no), severity (mild, moderate, severe; for COVID-19 infection only) and duration of symptom exacerbation (in days) for the following symptoms were evaluated: dizziness, nausea, weakness, palpitations, lightheadedness, tremulousness, blurred vision, concentration difficulties, memory difficulties, orthostatic leg and/or arm pain, gastrointestinal symptoms, sleep disturbances, restless legs syndrome and orthostatic headache. <br><br>Our observations suggest that mRNA vaccines are not associated with a higher frequency of acute side effects in patients with POTS. Symptom exacerbation as a consequence of mRNA vaccination seems to be less frequent and of shorter duration compared to patients who suffered a COVID-19 infection.</div> <div class="abstract-text is-expanded js-article-abstract"> </div> <div class="abstract-text is-expanded js-article-abstract">This study was carried out in accordance with the recommendations of the local ethics committee (Kantonale Ethikkommission Bern, Switzerland, project-ID: 2021-02115; 02.11.2021).</div> </div>
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
ClinicalTrials.gov study NCT05829356. IPD Sharing: YES. Countries: 2. Publications: 0.
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
ClinicalTrials.gov study NCT06118151. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.